Facidase Injection

Hyaluronidase
Sun Pharmaceutical Industries Ltd.
Pack size
Dispensing mode
Source
Agent
Retail Price

Indications

Facidase Injection is used for: Hypodermoclysis, Facilitate SC/IM inj, Aid in dispersal of extravasated fluids or blood, Aid in diffusion of local anesthesia in ophthalmology

Adult Dose

Skin Test 0.02 (3 units) of 150 units/mL solution intredermally; a wheal with pseudopods appearing within 5 min and persisting for 20-30 min with itching will indicate positive hypersensitivity reaction Absorption/Dispersion of Injected Drugs Add 50-300 units (typically 150 units) to the injection solution Hypodermoclysis Amphadase/Hylenex: Inject 150 units prior to SC fluid administration; this will facilitate absorption of 1000 mL or more of solution Vitrase: Inject 200 units prior to SC fluid administration; this will facilitate absorption of 1000 mL or more of solution Adjunct Subcutaneous Urography Improves resorption of radiopaque agents; indicated when intravenous administration cannot be successfully accomplished, with the patient prone Inject 75 units SC over each scapula, followed by injection of the contrast medium at the same sites

Child Dose

Skin Test 0.02 (3 units) of 150 units/mL solution intradermally; a wheal with pseudopods appearing within 5 min and persisting for 20-30 min with itching will indicate positive hypersensitivity reaction Hypodermoclysis Children > 3 years: May be added to small volumes of solution (up to 200 mL), such as or solutions of drugs for SC injection Infants and children < 3 years: Volume of a single clysis should be limited to 200 mL For premature infants or during the neonatal period: Do not exceed a daily dosage of 25 mL/kg of body weight; rate of administration should not be greater than 2 mL/min Adjunct in Subcutaneous Urography Used when IV administration cannot be successfully accomplished, particularly in infants and small children, with the patient prone Inject 75 units SC over each scapula, followed by injection of the contrast medium at the same sites

Renal Dose

Administration

Contra Indications

Hypersensitivity, malignancy. Direct application to the cornea, reduction of swelling of bites or stings. Inj into or around infected area. IV admin; unexplained premature labour.

Precautions

Impaired renal function. Infants, elderly. Patients with infections. Pregnancy, lactation. Lactation: It is not known whether hyaluronidase is excreted in human milk; caution should be exercised

Pregnancy-Lactation

Interactions

Action potentiated by urokinase especially in the treatment of MI. May increase absorption and toxicity of local anaesthetics. Heparin, salicylates and NSAIDs may inhibit the spreading action and efficacy of hyaluronidase.

Adverse Effects

Side effects of Hyaluronidase : <1% Angioedema, urticaria, allergic reactions (<0.1%) Frequency Not Defined Edema,Local injection site reactions Potentially Fatal: Hypersensitivity and anaphylaxis.

Mechanism of Action

Hyaluronidase is an enzyme which reduces the viscosity of ground substance, thus making the tissues more permeable to injected fluids. It facilitates distribution and absorption of locally injected substances. It also promotes resorption of excess fluids and extravasated blood in the tissues.

Note

Facidase Injection manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Hyaluronidase. Facidase is availble in Nepal. Farmaco Nepal drug index information on Facidase Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Hyaluronidase :